Brave new world: Cannabis for all? Some psychiatric remarks;Schöne neue welt: Cannabis für alle? Anmerkungen aus psychiatrischer sicht

Psychiatrische Praxis

Volumn 30, Issue 4, 2003, Pages 179-181

  Hambrecht, Martin ^a,b  

^a Klinik fur Psychiat/Psychotherapie   (Germany)

^b Evang Krankenhaus Elisabethenstift GGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; TETRAHYDROCANNABINOL;

CANNABIS ADDICTION; DRUG LEGISLATION; EDITORIAL; GOVERNMENT; HUMAN; POLICY; RISK ASSESSMENT;

EID: 0038465949     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39497     Document Type: Editorial

References (22)

1. Nedelmann C. Das Verbot von Cannabis ist ein kollektiver Irrweg. Deutsches Ärzteblatt 2000; 97: A 2833-2835
2. Gold MS. Marijuana. In: Miller NS: Comprehensive Handbook of Alcohol and Drug Addiction. New York: Marcel Decker, 1991: 353-376
3. Ashton CH. Pharmacology and effects of cannabis: a brief review. Brit J Psychiat 2001; 178: 101-106
4. British Medical Association. Therapeutic uses of cannabis. London: Harwood Academic, 1997
5. Thomas H. Psychiatric symptoms in cannabis users. Brit J Psychiat 1993; 163: 141-149
6. Thomas H. A community survey of adverse effects of cannabis use. Drug Alc Depend 1996; 42: 201-207
7. Troisi A, Pasini A, Saracco M et al. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 1998; 93: 487-492
8. Reilly D, Didcott R, Swift W et al. Long-term cannabis use: characteristics of users in Australian rural areas. Addiction 1998; 93: 837-846
9. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Medicine 1986; 16: 515-520
10. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiat 1972; 33: 383-386
11. Hall W, Solowij N, Lemon J. The Health and Social Consequences of Cannabis Use. Monograph Series No. 25. Canberra: Australian Government Publishing Service, 1994
12. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia - an epidemiological perspective. Austral New Zealand J Psychiat 2000; 34: 468-475
13. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224-230
14. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Arch Gen Psychiat 1994; 51: 273-279
15. Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. Aviation & Space Environmental Medicine 1991; 62: 221-227
16. Jones A. Psychiatric effects of cannabis. Brit J Psychiat 2001; 178: 116-122
17. World Health Organization. Programme on Substance Abuse. Cannabis: A Health Perspective and Research Agenda. Geneva: WHO, 1997
18. Morgenstern J, Langenbucher J, Labouvie EW. The generalizability of the dependence syndrome across substances: an examination of some properties of the proposed DSM-IV dependence criteria. Addiction 1994; 89: 1105-1113
19. Wiesbeck GA, Schuckit MA, Kalmijn JA et al. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469-1478
20. Manzanares J, Corchero J, Romero JJ et al. Pharmacological and biochemical interactions between opiates and cannabinoids. Trends in Pharmacological Sciences 1999; 20: 287-294
21. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mul opioid receptor mechanism. Science 1997; 276 (5321): 2048-2050
22. Rommelspacher H. Cannabis. Als Arzneimittel nur von geringem therapeutischen Nutzen. Deutsches Arzteblatt 2000; 97: B 2918-2920